SEARCH

SEARCH BY CITATION

References

  • 1
    Alexandre L, Clark AB, Cheong E, Lewis MP, Hart AR. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Aliment Pharmacol Ther 2012; 36: 30111.
  • 2
    Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58 (Suppl. 3): 1418.
  • 3
    Sadaria MR, Reppert AE, Yu JA, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011; 142: 115260.
  • 4
    Fang D, Das KM, Cao W, et al. Barrett's esophagus: progression to adenocarcinoma and markers. Ann NY Acad Sci 2011; 1232: 21029.
  • 5
    Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012; 21: 45661.
  • 6
    Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012; 24: 91723.
  • 7
    Beales IL, Vardi I, Dearman L, Brougton T. Statin use is associated with a reduced incidence of esophageal adenocarcinoma. Dis Esophagus 2012 [Epub ahead of print].